Why Immutep Limited’s (IMMP) Stock Is Down 5.07%
As of Friday, July 17, Immutep Limited’s IMMP share price has dipped by 5.07%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
Commentary & Analysis
Why Immutep Limited’s (IMMP) Stock Is Up 5.56%
As of Monday, July 13, Immutep Limited’s IMMP share price has surged by 5.56%, which has investors questioning if this is right time to sell.Michael Rose
Why Immutep Limited’s (IMMP) Stock Is Down 5.12%
As of Wednesday, July 08, Immutep Limited’s IMMP share price has dipped by 5.12%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Immutep Limited’s (IMMP) Stock Is Down 5.36%
As of Friday, June 26, Immutep Limited’s IMMP share price has dipped by 5.36%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Immutep Limited’s (IMMP) Stock Is Down 5.60%
As of Wednesday, June 03, Immutep Limited’s IMMP share price has dipped by 5.60%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $56.0 | $292.6 | 16% |
|
| Shares Out (Mil) | 981.1 | 54.4 | 94% |
|
| Institutional Ownership | 95.3% | 93.2% | 67% |
|
| Float (Mil) | 1,430.3 | 40.2 | 94% |
|
| Beta | 2.36 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 100 | 544 | 35% |
|
| Price Change (52-week) |
(77.7%) | 59.7% | 7% |
|
| Growth | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (19.1%) | 13.6% | 3% |
|
| Net Income (5yr) | (34.1%) | (10.1%) | 12% |
|
| EPS (5yr) | (4.0%) | 16.0% | 26 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (38.0%) | (15.6%) | 13% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $5 | $37 | 6% |
|
| Net Income (TTM) (Mil) | ($56) | ($43) | 15% |
|
| EPS (TTM) | ($0.038) | ($1.400) | 38% |
|
| Operating Cash Flow (TTM) (Mil) | ($42) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($1) | $2 | 41% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | ($6) | $164 | 2% |
|
| Valuation | IMMP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.65 | 2.83 | 89% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMMP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (943.9%) | 64.2% | 0% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (53.1%) | (47.5%) | 11% |
|
| ROE | (64.8%) | (55.0%) | 13% |
|
| Liabilities to Assets | 32.8% | 29.6% | 24% |
|
| F-Score | 2 | 3 | 7% |
|
Immutep Limited did not pass any screens on 8/21/2026.
